| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Ferring Pharms. Inc. v. Novel Labs., Inc., 17-0894 (D. Del.) | July 5, 2017 | Hon. Richard G. Andrews | Prepopik® (sodium picosulfate / magnesium oxide / citric acid oral solution) |
8,450,338
8,481,083
9,669,110
|
| Sebela Int’l Ltd. V. Prinston Pharm. Inc., 17-4964 (D.N.J.) | July 6, 2017 | Hon. Claire C. Cecchi | Brisdelle® (paroxetine capsules) | 9,393,237 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc., 17-5005 (D.N.J.) | July 7, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Actelion Pharms. Ltd. v. Sun Pharm. Indus., Inc., 17-5015 (D.N.J.) | July 7, 2017 | Hon. Peter G. Sheridan | Veletri® (epoprostenol sodium for injection) | 8,598,227 |
| Duke University v. Sandoz Inc., 17-0528 (E.D. Tex.) | July 7, 2017 | Hon. Rodney Gilstrap | Latisse® (bimatoprost ophthalmic solution) | 9,579,270 |
| Dr. Reddy’s Labs., Inc. v. Icos Corp., IPR2017-01757 (PTAB) | July 10, 2017 | N/A | Cialis® (tadalafil tablets) | 6,943,166 |
| KVK-Tech, Inc. v. Silvergate Pharms., Inc., PGR2017-00039 (PTAB) | July 10, 2017 | N/A | Qbrelis® (lisinopril oral solution) | 9,463,183 |
| Eli Lilly and Co. v. MacLeods Pharma USA, Inc., 17-5087 (D.N.J.) | July 12, 2017 | Hon. Michael A. Shipp | Cialis® (tadalafil tablets) | 6,943,166 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 17-5100 (D.N.J.) | July 12, 2017 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,629,965 |
| Argentum Pharms. LLC v. Icos Corp., IPR2017-01762 (PTAB) | July 12, 2017 | N/A | Cialis® (tadalafil tablets) | 6,943,166 |
| Gilead Sciences, Inc. v. Amneal Pharms. LLC, 17-0943 (D. Del.) | July 13, 2017 | Vacant Judgeship (2017) | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
|
| Par Pharm., Inc. v. Hospira, Inc., 17-0944 (D. Del.) | July 13, 2017 | Vacant Judgeship (2017) | Adrenalin® (epinephrine for injection) |
9,119,876
9,295,657
|
| Mitsubishi Tanabe Pharma Corp. v. Prinston Pharms., Inc., 17-5135 (D.N.J.) | July 13, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Galderma Labs., L.P. v. Perrigo UK Finco Ltd., 17-1860 (N.D. Tex.) | July 13, 2017 | Hon. Barbara M.G. Lynn | Soolantra® (ivermectin cream) |
8,815,816
9,089,587
9,233,117
9,233,118
|
| Par Pharm., Inc. v. Horizon therapeutics, Inc., IPR2017-01767 (PTAB) | July 13, 2017 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,254,278 |
| Par Pharm., Inc. v. Horizon therapeutics, Inc., IPR2017-01768 (PTAB) | July 13, 2017 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,095,559 |
| Par Pharm., Inc. v. Horizon therapeutics, Inc., IPR2017-01769 (PTAB) | July 13, 2017 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,326,966 |
| Biogen Int’l GMBH v. Zydus Pharms. (USA) Inc., 17-0954 (D. Del.) | July 14, 2017 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,320,999
8,399,514
|
| Delcor Asset Corp. v. Taro Pharm. Indus., Ltd., 17-0970 (D. Del.) | July 17, 2017 | Hon. Richard G. Andrews | Evoclin® (clindamycin phosphate aerosol foam) |
7,141,237
7,374,747
|
| Delcor Asset Corp. v. Taro Pharm. Indus., Ltd., 17-5405 (S.D.N.Y.) | July 17, 2017 | Hon. Richard J. Sullivan | Evoclin® (clindamycin phosphate aerosol foam) |
7,141,237
7,374,747
|
| Epic Pharma, LLC v. Pfizer Inc., 17-0987 (D. Del.) | July 19, 2017 | Hon. Gregory M. Sleet | Zithromax® (azithromycin oral suspension) | 6,268,489 |
| Mitsubishi Tanabe Pharma Corp. v. Apotex, Inc., 17-5278 (D.N.J.) | July 19, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Mitsubishi Tanabe Pharma Corp. v. Apotex, Inc., 17-0990 (D. Del.) | July 20, 2017 | Hon. Gregory M. Sleet | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Mitsubishi Tanabe Pharma Corp. v. MSN Labs. Private Ltd., 17-5302 (D.N.J.) | July 20, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 17-5314 (D.N.J.) | July 20, 2017 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,189,740
8,404,717
9,056,120
|
| Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., 17-5319 (D.N.J.) | July 20, 2017 | Hon. Michael A. Shipp | Invokana® (canagliflozin tablets) |
7,943,788
8,222,219
8,785,403
|
| Precision Dermatology, Inc. v. Lupin Ltd., 17-5333 (D.N.J.) | July 20, 2017 | Hon. Peter G. Sheridan | Locoid® (hydrocortisone butyrate lotion) | 7,981,877 |
| Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., 17-1781 (D. Col.) | July 21, 2017 | Hon. R. Brooke Jackson | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Mitsubishi Tanabe Pharma Corp. v. Sandoz Inc., 17-1782 (D. Col.) | July 21, 2017 | Hon. Kristen L. Mix | Invokana® (canagliflozin tablets) | 7,943,788 |
| Mitsubishi Tanabe Pharma Corp. v. Teva Pharms. USA, Inc., 17-0998 (D. Del.) | July 21, 2017 | Hon. Gregory M. Sleet | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Bristol-Myers Squibb Co. v. Zydus Pharms. (USA) Inc., 17-5337 (D.N.J.) | July 21, 2017 | Hon. Peter G. Sheridan | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Merck Sharp & Dohme Corp. v. Apotex Inc., 17-5399 (D.N.J.) | July 24, 2017 | Hon. Peter G. Sheridan | Emend® (fosaprepitant dimeglumine for injection) | 5,691,336 |
| Takeda Pharms. U.S.A., Inc. v. Granules Pharms. Inc., 17-1019 (D. Del.) | July 25, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Takeda Pharms. U.S.A., Inc. v. Hetero Labs Ltd., 17-1020 (D. Del.) | July 25, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Bayer AG v. Mayne Pharma LLC, 17-1037 (D. Del.) | July 27, 2017 | Hon. Leonard P. Stark | Natazia® (estradiol valerate / dienogest tablets) | 8,071,577 |
| Gilead Sciences, Inc. v. Macleods Pharms., Ltd., 17-1039 (D. Del.) | July 27, 2017 | Vacant Judgeship (2017) | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245
6,703,396
8,592,397
8,716,264
9,457,036
|
| Jazz Pharms., Inc. v. Ascent Pharms., Inc., 17-5487 (D.N.J.) | July 27, 2017 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
6,472,431
6,780,889
7,262,219
7,851,506
8,263,650
8,324,275
8,461,203
7,668,730
7,765,106
7,765,107
7,895,059
8,457,988
8,589,182
8,731,963
8,772,306
8,859,619
8,952,062
9,539,330
9,486,426
9,050,302
|
| Jazz Pharms., Inc. v. Ascent Pharms., Inc., 17-4439 (E.D.N.Y.) | July 27, 2017 | Hon. Pamela K. Chen | Xyrem® (sodium oxybate oral solution) |
6,472,431
6,780,889
7,262,219
7,851,506
8,263,650
8,324,275
8,461,203
7,668,730
7,765,106
7,765,107
7,895,059
8,457,988
8,589,182
8,731,963
8,772,306
8,859,619
8,952,062
9,539,330
9,486,426
9,050,302
|
| Bayer Intellectual Property GMBH v. Lupin Ltd., 17-1047 (D. Del.) | July 28, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Allergan, Inc. v. Taro Pharms., Inc., 17-1048 (D. Del.) | July 28, 2017 | Vacant Judgeship (2017) | Aczone® (dapsone gel) | 9,517,219 |
| Endo Pharms. Inc. v. Lupin Atlantis Holdings SA, 17-0558 (E.D. Tex.) | July 28, 2017 | Hon. Rodney Gilstrap | Nascobal® (cyanocobalamin nasal spray) |
7,229,636
7,404,489
7,879,349
8,003,353
8,940,714
9,415,007
|
| AstraZeneca LP v. Invagen Pharms. Inc., 17-1073 (D. Del.) | Aug. 2, 2017 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
RE 46,276
7,250,419
7,265,124
|
| Insys Therapeutics, Inc. v. Endo Generics Holdings, Inc., 17-1078 (D. Del.) | Aug. 3, 2017 | Hon. Leonard P. Stark | Syndros® (dronabinol oral solution) |
8,222,292
9,345,771
|
| Horatio Washington Depot Technologies LLC v. Tolmar, Inc., 17-1086 (D. Del.) | Aug. 3, 2017 | Hon. Leonard P. Stark | Eligard® (leuprolide acetate for injection) |
5,932,547
6,124,261
6,235,712
|
| Fresenius-Kabi USA LLC v. AstraZeneca AB, IPR2017-01910 (PTAB) | Aug. 4, 2017 | N/A | Faslodex® (fulvestrant for injection) | 6,774,122 |
| Fresenius-Kabi USA LLC v. AstraZeneca AB, IPR2017-01912 (PTAB) | Aug. 4, 2017 | N/A | Faslodex® (fulvestrant for injection) | 8,466,139 |
| Fresenius-Kabi USA LLC v. AstraZeneca AB, IPR2017-01913 (PTAB) | Aug. 4, 2017 | N/A | Faslodex® (fulvestrant for injection) | 8,329,680 |
| Insys Therapeutics, Inc. v. Endo Generics Holdings, Inc., 17-5955 (S.D.N.Y.) | Aug. 7, 2017 | Hon. William H. Pauley, III | Syndros® (dronabinol oral solution) |
8,222,292
9,345,771
|
| Horizon Therapeutics, LLC v. Lupin Ltd., 17-5900 (D.N.J.) | Aug. 8, 2017 | Hon. Kevin McNulty | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,561,197 |
| Horizon Therapeutics, LLC v. Par Pharm., Inc., 17-5901 (D.N.J.) | Aug. 8, 2017 | Hon. Kevin McNulty | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,561,197 |
| Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp., 17-5914 (D.N.J.) | Aug. 8, 2017 | Hon. Stanley R. Chesler | Lantus® (insulin glargine injection) |
7,476,652
7,713,930
|
| Bayer Intellectual Property GMBH v. Breckenridge Pharm., Inc., 17-1129 (D. Del.) | Aug. 11, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 17-1131 (D. Del.) | Aug. 11, 2017 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,669,023
9,669,024
9,675,610
9,675,611
9,682,077
|
| Aptalis Pharma US, Inc. v. Amneal Pharms. LLC, 17-1134 (D. Del.) | Aug. 11, 2017 | Hon. Leonard P. Stark | Canasa® (mesalamine rectal suppository) |
7,541,384
8,217,083
8,436,051
|
| Aptalis Pharma US, Inc. v. Amneal Pharms. LLC, 17-6090 (D.N.J.) | Aug. 11, 2017 | Hon. Claire C. Cecchi | Canasa® (mesalamine rectal suppository) |
7,541,384
8,217,083
8,436,051
|
| Eli Lilly and Co. v. Eagle Pharms., Inc., 17-2772 (S.D. Ind.) | Aug. 14, 2017 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed for injection) | 7,772,209 |
| Celgene Corp. v. Cipla Ltd., 17-6163 (D.N.J.) | Aug. 15, 2017 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
7,465,800
7,855,217
7,968,569
8,530,498
8,648,095
9,101,621
9,101,622
|
| Actavis Elizabeth LLC v. Novartis A.G., IPR2017-01946 (PTAB) | Aug. 15, 2017 | N/A | Gilenya® (fingolimod capsules) | 9,187,405 |
| Cephalon, Inc. v. Slayback Pharma LLC, 17-1154 (D. Del.) | Aug. 16, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) | 8,791,270 |
| Sun Pharm. Indus., Ltd. v. Novartis A.G., IPR2017-01929 (PTAB) | Aug. 16, 2017 | N/A | Gilenya® (fingolimod capsules) | 9,187,405 |
| Onyx Therapeutics, Inc. v. Innopharma Inc., 17-1155 (D. Del.) | Aug. 17, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
|
| Kissei Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 17-1161 (D. Del.) | Aug. 18, 2017 | Hon. Leonard P. Stark | Rapaflo® (silodosin capsules) | 5,387,603 |
| Bayer Intellectual Property GMBH v. Torrent Pharms., Ltd., 17-1163 (D. Del.) | Aug. 18, 2017 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Teva Pharms. Int’l GMBH v. Apotex Inc., 17-1164 (D. Del.) | Aug. 18, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) |
8,791,270
8,609,707
9,265,831
9,572,796
9,572,797
9,034,908
9,144,568
9,572,887
9,597,397
9,597,398
9,597,399
9,000,021
9,579,384
|
| Eli Lilly and Co. v. Jiangsu Hansoh Pharm. Group Co., Ltd., 17-2864 (S.D. Ind.) | Aug. 21, 2017 | Hon. Richard L. Young | Alimta® (pemetrexed disodium for injection) | 7,772,209 |
| Eli Lilly and Co. v. Apotex, Inc., 17-2865 (S.D. Ind.) | Aug. 21, 2017 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed for injection) | 7,772,209 |
| Mitsubishi Tanabe Pharma Corp. v. Invagen Pharms., Inc., 17-6375 (D.N.J.) | Aug. 23, 2017 | Hon. Freda L. Wolfson | Invokamet® (metformin HCl tablets) | 7,943,788 |
| Abbvie Inc. v. Macleods Pharms., Ltd., 17-1199 (D. Del.) | Aug. 24, 2017 | Hon. Richard G. Andrews | Kaletra® (lopinavir / ritonavir tablets) |
7,148,359
7,364,752
8,025,899
8,268,349
8,309,613
8,377,952
8,399,015
8,470,347
8,691,878
|
| Teva Pharms. Int’l GMBH v. Fresenius Kabi USA, LLC, 17-1201 (D. Del.) | Aug. 24, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) |
8,791,270
8,609,707
9,265,831
9,572,796
9,572,797
9,034,908
9,144,568
9,572,887
9,597,397
9,597,398
9,597,399
9,000,021
9,579,384
|
| Onyx Therapeutics, Inc. v. Apotex Inc., 17-1202 (D. Del.) | Aug. 24, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Mylan Pharms. Inc. v. Pozen Inc., IPR2017-01995 (PTAB) | Aug. 24, 2017 | N/A | Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) | 9,220,698 |
| Forest Labs., LLC v. Aurobindo Pharma Ltd., 17-1210 (D. Del.) | Aug. 25, 2017 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) |
7,304,036
7,371,727
7,704,947
7,745,409
8,080,526
8,110,553
|
| BTG Int’l Ltd. v. Teva Pharms. USA, Inc., 17-6435 (D.N.J.) | Aug. 25, 2017 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Valeant Pharms. Int’l, Inc. v. Par Sterile Products, LLC, 17-6449 (D.N.J.) | Aug. 25, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide for injection) |
8,247,425
8,420,663
8,552,025
8,822,490
9,180,125
9,669,096
|
| Valeant Pharms. Int’l, Inc. v. Par Sterile Products, LLC, 17-6557 (S.D.N.Y.) | Aug. 28, 2017 | Hon. Paul A. Engelmayer | Relistor® (methylnaltrexone bromide for injection) |
8,247,425
8,420,663
8,552,025
8,822,490
9,180,125
9,669,096
|
| Onyx Therapeutics, Inc. v. Qilu Pharma, Inc., 17-1235 (D. Del.) | Aug. 30, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Alcon Research, Ltd. v. Cipla Ltd., 17-1244 (D. Del.) | Aug. 31, 2017 | Hon. Gregory M. Sleet | Pazeo® (olopatadine HCl ophthalmic solution) |
8,791,154
9,533,053
|
| Sanofi v. Aurobindo Pharma USA, Inc., 17-1247 (D. Del.) | Aug. 31, 2017 | Hon. Richard G. Andrews | Multaq® (dronedarone tablets) |
8,410,167
9,107,900
|
| Valeant Pharms. Int’l, Inc. v. Mylan Pharms., Inc., 17-6714 (D.N.J.) | Sept. 1, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide for injection) | 9,669,096 |
| Bristol-Myers Squibb Co. v. Emcure Pharms. Ltd., 17-6832 (D.N.J.) | Sept. 6, 2017 | Hon. Peter G. Sheridan | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Celgene Corp. v. Lotus Pharm Co., Ltd., 17-6842 (D.N.J.) | Sept. 6, 2017 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) |
5,635,517
6,315,720
6,561,977
6,755,784
7,189,740
7,465,800
7,855,217
7,968,569
8,315,886
8,404,717
8,530,498
8,626,531
8,648,095
9,056,120
9,101,621
9,101,622
|
| Janssen Products, L.P. v. Aurobindo Pharma Ltd., 17-6872 (D.N.J.) | Sept. 7, 2017 | Hon. William H. Walls | Prezista® (darunavir tablets) |
8,518,987
7,700,645
7,126,015
7,595,408
|
| Forest Labs., LLC v. Breckenridge Pharm., Inc., 17-1287 (D. Del.) | Sept. 8, 2017 | Hon. Mitchell S. Goldberg | Saphris® (asenapine maleate tablets) | 5,763,476 |
| Allergan, Inc. v. Aurobindo Pharma Ltd., 17-1290 (D. Del.) | Sept. 8, 2017 | Hon. Gregory M. Sleet | Lastacaft® (alcaftadine ophthalmic solution) | 8,664,215 |
| U.S. Dept. of Health and Human Services v. Aurobindo Pharma USA, Inc., 17-6911 (D.N.J.) | Sept. 8, 2017 | Hon. Michael A. Shipp | Prezista® (darunavir tablets) |
7,470,506
8,597,876
|
| Merck Sharp & Dohme Corp. v. Teva Pharms. USA, Inc., 17-6921 (D.N.J.) | Sept. 8, 2017 | Hon. Michael A. Shipp | Entereg® (alvimopan capsules) |
6,469,030
8,946,262
|
| Eli Lilly and Co. v. Eagle Pharms., Inc., 17-1293 (D. Del.) | Sept. 11, 2017 | Vacant Judgeship (2017) | Alimta® (pemetrexed for injection) | 7,772,209 |
| Eli Lilly and Co. v. Glenmark Pharms. Ltd., 17-7024 (D.N.J.) | Sept. 12, 2017 | Hon. Katharine S. Hayden | Cialis® (tadalafil tablets) | 6,943,166 |
| Insys Therapeutics, Inc. v. Teva Pharms. USA, Inc., 17-1303 (D. Del.) | Sept. 13, 2017 | Hon. Gregory M. Sleet | Subsys® (fentanyl sublingual spray) |
8,486,972
8,486,973
8,835,459
8,835,460
9,241,935
9,289,387
9,642,797
9,642,844
|
| Sandoz Inc. v. Duke University, 17-0823 (M.D.N.C.) | Sept. 14, 2017 | Hon. Catherine C. Eagles | Latisse® (bimatoprost ophthalmic solution) | 9,579,270 |
| Indivior Inc. v. Alvogen Pine Brook, Inc., 17-7106 (D.N.J.) | Sept. 14, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Dr. Reddy’s Labs. S.A., 17-7111 (D.N.J.) | Sept. 14, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Teva Pharms. USA, Inc., 17-7115 (D.N.J.) | Sept. 14, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Par Pharm., Inc., 17-7020 (S.D.N.Y.) | Sept. 14, 2017 | Hon. Katherine B. Forrest | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Actavis Labs. UT, Inc., 17-1034 (D. Utah) | Sept. 14, 2017 | Hon. Dustin B. Pead | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Indivior Inc. v. Mylan Technologies, Inc., 17-0157 (N.D.W.V.) | Sept. 14, 2017 | Hon. Irene M. Keeley | Suboxone® (buprenorphine HCl naloxone HCl sublingual film) | 9,687,454 |
| Teijin Ltd. v. Aurobindo Pharma Ltd., 17-1314 (D. Del.) | Sept. 15, 2017 | Vacant Judgeship (2017) | Uloric® (febuxostat tablets) |
6,255,474
7,361,676
8,372,872
9,107,912
|
| Forest Labs., LLC v. Prinston Pharm. Inc., 17-7191 (D.N.J.) | Sept. 18, 2017 | Hon. Brian R. Martinotti | Byvalson® (nebivolol / valsartan tablets) |
7,803,838
7,838,552
|
| Valeant Pharms. Int’l, Inc. v. Actavis LLC, 17-7206 (D.N.J.) | Sept. 18, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide for injection) |
9,669,096
9,492,445
|
| Purdue Pharma L.P. v. Par Pharm., Inc., 17-1334 (D. Del.) | Sept. 20, 2017 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) |
9,492,389
9,492,391
9,492,392
9,492,393
|
| Takeda Pharm. Co. Ltd. v. Indoco Remedies Ltd., 17-7301 (D.N.J.) | Sept. 20, 2017 | Hon. Stanley R. Chesler | Nesina® (alogliptin benzoate tablets) |
7,807,689
8,173,663
8,288,539
8,697,125
|
| Purdue Pharma L.P. v. Par Pharm., Inc., 17-1582 (D. Conn.) | Sept. 21, 2017 | Hon. Stefan R. Underhill | OxyContin® (oxycodone HCl extended-release tablets) |
9,492,389
9,492,391
9,492,392
9,492,393
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 17-11814 (D. Mass.) | Sept. 21, 2017 | Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone HCl extended-release tablets)
Xtampza® ER (oxycodone extended-release capsules)
|
9,693,961 |
| Mitsubishi Tanabe Pharma Corp. v. Prinston Pharms., Inc., 17-7342 (D.N.J.) | Sept. 21, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) | 8,513,202 |
| Shionogi Inc. v. Qingdao Baheal Pharm. Co. Ltd., 17-1347 (D. Del.) | Sept. 22, 2017 | Hon. Mitchell S. Goldberg | Fortamet® (metformin extended-release tablets) |
6,790,459
6,866,866
|
| Sucampo AG v. Teva Pharm. Indus. Ltd., 17-7451 (D.N.J.) | Sept. 25, 2017 | Hon. Peter G. Sheridan | Amitiza® (lubiprostone capsules) |
6,414,016
8,071,613
7,795,312
6,982,283
8,097,653
8,389,542
8,026,393
8,338,639
8,748,481
|
| Duke University v. Alembic Pharms., Ltd., 17-7453 (D.N.J.) | Sept. 25, 2017 | Hon. Brian R. Martinotti | Latisse® (bimatoprost ophthalmic solution) | 9,579,270 |
| Biogen Int’l GMBH v. Teva Pharms. USA, Inc., 17-1361 (D. Del.) | Sept. 27, 2017 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376
7,320,999
|
| Wyeth LLC v. Sun Pharm. Indus. Ltd., 17-1362 (D. Del.) | Sept. 28, 2017 | Hon. Richard G. Andrews | Bosulif® (bosutinib tablets) |
7,417,148
7,919,625
|
